Propanc Biopharma, Inc.
PPCB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $22 | $18 | $0 |
| Gross Profit | $0 | -$22 | -$18 | -$6 |
| % Margin | – | – | – | – |
| R&D Expenses | $224 | $248 | $248 | $256 |
| G&A Expenses | $57,054 | $1,288 | $1,529 | $1,735 |
| SG&A Expenses | $57,054 | $1,288 | $1,529 | $1,729 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $57,278 | $1,514 | $1,759 | $1,985 |
| Operating Income | -$57,278 | -$1,536 | -$1,777 | -$1,991 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1,645 | -$414 | -$1,014 | -$722 |
| Pre-Tax Income | -$58,923 | -$1,950 | -$2,790 | -$2,713 |
| Tax Expense | $0 | -$129 | -$130 | -$55 |
| Net Income | -$58,923 | -$1,821 | -$2,661 | -$2,658 |
| % Margin | – | – | – | – |
| EPS | -14.85 | -1,420.95 | -31,268.39 | -1,119,475.67 |
| % Growth | 99% | 95.5% | 97.2% | – |
| EPS Diluted | -14.85 | -1,200 | -31,268.39 | -1,119,475.67 |
| Weighted Avg Shares Out | 3,968 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 3,968 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $6 |
| Interest Expense | $564 | $666 | $533 | $569 |
| Depreciation & Amortization | $20 | $22 | $23 | $2 |
| EBITDA | -$58,339 | -$1,262 | -$2,235 | -$2,139 |
| % Margin | – | – | – | – |